XGN

Exagen Inc. (XGN) Q2 2024 10-Q Summary

Business Context and Reporting Period

Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease decision-making, primarily through its AVISE® CTD test. This report covers the quarterly period ended June 30, 2024. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 1, 2024, there were 17,386,389 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 6.6% QoQ and 16.2% YoY (YTD). This growth was driven by improved Average Selling Price (ASP) and $3.1 million (Q2) / $5.1 million (YTD) in revenue adjustments from prior periods due to better-than-expected collections.
• Volume Decline: Despite revenue growth, the volume of AVISE® CTD tests delivered declined approximately 13% in Q2 and 16% YTD compared to 2023. This was attributed to revenue cycle management initiatives, including withholding claim submissions to optimize appeals.
• Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 12.5% QoQ and 11.9% YTD, primarily due to reduced headcount, lower legal settlement costs, and decreased stock-based compensation.
• Profitability Improvement: Net loss narrowed significantly compared to the prior year periods, with the YTD 2024 loss of $6.3 million representing a 50% reduction from the $12.7 million loss in YTD 2023.

Outlook, Risks, and Management Commentary

• Product Pipeline: Management plans to incorporate new T-Cell Biomarkers (TC4d, TIgG, TIgM) and RA Sub-Profile Biomarkers into the AVISE® CTD test by the end of 2024. These additions aim to improve diagnostic sensitivity for lupus and seronegative rheumatoid arthritis.
• Liquidity: The company holds $24.5 million in cash and believes existing resources are sufficient to fund operations for at least 12 months. However, it expects to continue incurring net losses and may require additional equity or debt financing in the future.
• Regulatory Risks: The FDA issued a final rule in May 2024 to regulate Laboratory Developed Tests (LDTs) as medical devices, effective July 5, 2024. This could require Exagen to conduct additional clinical trials and obtain pre-market approval, potentially increasing costs and delaying product launches. Litigation challenging this rule is ongoing.
• Debt Covenants: The company is in compliance with its amended 2017 Term Loan covenants, which include minimum liquidity requirements and revenue targets (waived if cash balances exceed 50% of the loan principal).
• Legal Proceedings: A qui tam lawsuit regarding historical specimen processing arrangements was partially settled in October 2023 ($0.7 million payment), but non-covered conduct remains pending with motions to amend the complaint still active.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of revenue growth given the 13-16% decline in test volumes; assess reliance on "catch-up" revenue from prior period adjustments.
• Regulatory Impact: Monitor the implementation timeline of the FDA's LDT final rule and the outcome of the ACLA lawsuit challenging it, as this could materially alter the cost structure and go-to-market strategy.
• Cash Burn Rate: Track the $11.5 million operating cash burn for the first half of 2024 against the $24.5 million cash balance to confirm the 12-month runway.
• Payor Mix: Review the concentration of revenue from Medicare (25% YTD) and Medicare Advantage (21% YTD) and the impact of the new MolDX/Z-Code requirements on reimbursement.
• Debt Obligations: Confirm adherence to the Innovatus loan covenants, specifically the minimum liquidity threshold of $2.0 million and the revenue covenant waiver conditions.